BFC Planning’s Allogene Therapeutics ALLO Stock Holding History
Bought
Maintained
Sold
Other funds holding ALLO
BFC Planning's ALLO Position: Q3 2026 in Review
BFC Planning opened a new position in Allogene Therapeutics (ALLO) in Q3 2026: 173,000 shares worth $277K. The stake represents 0.01% of the portfolio and ranks #817 among its holdings. This is a return to the name: BFC Planning previously reported a position in ALLO as recently as Q1 2026.
BFC Planning first reported a position in ALLO in Q2 2025 and has held it in 5 quarters since. The position peaked at $703K in Q1 2026. 141 funds tracked by Wall St. Rank hold ALLO as of Q3 2026.
- BFC Planning held 173,000 shares of Allogene Therapeutics worth $277K as of Q3 2026.
- Allogene Therapeutics was a new BFC Planning position in Q3 2026.
- Allogene Therapeutics made up 0.01% of BFC Planning's portfolio in Q3 2026, its #817 holding.
- BFC Planning first reported a position in Allogene Therapeutics in Q2 2025 and has held it in 5 quarters since.
- BFC Planning's Allogene Therapeutics position peaked at $703K in Q1 2026.
- 141 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q3 2026.
Based on BFC Planning's 13F filing for Q3 2026, filed 13 Nov 2026.